Russia's Chemrar plans to start making pharma vs COVID-19 by May

MOSCOW, Apr 9 (PRIME) -- Russian pharmaceutical company Chemrar plans to start producing Favipiravir, a medicine which is probably effective against the coronavirus, by May, Chairman of the Board of Directors Andrei Ivashchenko told PRIME in an interview published on Thursday.

"Our main goal today is to ensure production of the medicine by May to start treating patients in hospitals. We will raise production later to satisfy the entire potential demand and start retail sales of the drug," Ivashchenko said.

The retail sales can start in June, he said. 

The official said that Favipiravir is the only pharmaceutical whose effect was registered in hundreds of people who contracted the COVID-19.

A full treatment cycle with Favipiravir will cost up to 30,000–50,000 rubles, which is many times cheaper than the foreign analogue.

(77.7325 – U.S. $1)

End %%mk/jst%%